Tag: Salvage therapy

Enfuvirtide, commonly known by its research code T20 and brand name Fuzeon, was the first-in-class HIV fusion inhibitor approved by the FDA in 2003, marking a significant milestone in antiretroviral therapy. This potent peptide drug revolutionized treatment for individuals with drug-resistant HIV by uniquely blocking the virus from entering healthy immune cells. However, the term 'T20' also appears as a pill imprint for many other medications, which can cause confusion.

The worldwide prevalence of *H. pylori* infection is estimated to be as high as 50%, yet a significant percentage of first-line treatments fail, largely due to antibiotic resistance. In this context, the fluoroquinolone antibiotic **levofloxacin** has emerged as a valuable component in more advanced strategies to eradicate the bacteria.

Approved by the FDA in 2003, enfuvirtide was the first HIV fusion inhibitor, representing a new class of antiretroviral drugs. This innovative medication provides a crucial treatment option for individuals whose virus has developed resistance to other HIV therapies by targeting the viral entry process.

First approved in 2003, enfuvirtide was a significant breakthrough as the first HIV fusion inhibitor, but it was primarily reserved for treatment-experienced patients with multi-drug resistant HIV-1. The drug, marketed under the brand name Fuzeon, addresses the critical need for a treatment option when standard regimens fail.